Company profile
LISATA THERAPEUTICS, INC.
NASDAQ:LSTABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PERIPHERAL BLOOD STEM/PROGENITOR CELLS, AUTOLOGOUS, CD34+, G-CSF MOBILIZED | phase2 | — | 4 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04614467 | phase2 | terminated | 2020-10-29 | 2022-09-28 | Lisata Therapeutics, Inc. | A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction |
| NCT05712356 | phase2 | completed | 2023-05-13 | 2026-04-05 | Lisata Therapeutics, Inc. | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors |
| NCT00300053 | phase2 | completed | 2006-04-01 | 2008-03-01 | Lisata Therapeutics, Inc. | ACT34-CMI -- Adult Autologous CD34+ Cells |
| NCT01875653 | phase3 | terminated | 2014-10-01 | 2016-01-01 | Lisata Therapeutics, Inc. | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma |
| NCT03517176 | phase1 | completed | 2018-07-31 | 2020-06-19 | Lisata Therapeutics, Inc. | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer |
FDA applications (0)
No records yet.